U.S. Markets open in 5 hrs 42 mins
  • S&P Futures

    3,714.75
    +5.75 (+0.16%)
     
  • Dow Futures

    29,719.00
    +50.00 (+0.17%)
     
  • Nasdaq Futures

    11,407.75
    +31.00 (+0.27%)
     
  • Russell 2000 Futures

    1,689.70
    +3.60 (+0.21%)
     
  • Crude Oil

    78.50
    -0.24 (-0.30%)
     
  • Gold

    1,654.30
    -1.30 (-0.08%)
     
  • Silver

    18.69
    -0.22 (-1.14%)
     
  • EUR/USD

    0.9684
    -0.0004 (-0.0387%)
     
  • 10-Yr Bond

    3.6970
    0.0000 (0.00%)
     
  • Vix

    31.35
    +4.00 (+14.63%)
     
  • GBP/USD

    1.0716
    -0.0140 (-1.2924%)
     
  • USD/JPY

    143.8160
    +0.4960 (+0.3461%)
     
  • BTC-USD

    18,914.43
    -162.84 (-0.85%)
     
  • CMC Crypto 200

    433.19
    -11.34 (-2.55%)
     
  • FTSE 100

    7,043.50
    +24.90 (+0.35%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

·1 min read

The adverse impact of the COVID-19 pandemic continued for Medical - Generic Drugs players in the first nine months of 2021, especially for cough and cold products. Uncertainty still lingers with the prevalence of the Delta variant and the emergence of the Omicron. Although pricing pressure in North American and European markets is stabilizing, it is still hurting the top line of generic drugmakers.

Product launches have been driving revenues of major generic drugmakers higher, which will likely continue in 2022. Companies like Dr. Reddy's Laboratories RDY, Teva Pharmaceutical TEVA and Amphastar Pharmaceuticals AMPH are poised to beat the COVID-19 challenge on the back of favorable macro factors.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Dr. Reddy's Laboratories Ltd (RDY) : Free Stock Analysis Report
 
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
 
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research